- Home
- SN vs BIIB Comparison
SN vs BIIB Comparison
Compare SN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SN
- BIIB
- Stock Information
- Founded
- SN 1993
- BIIB 1978
- Country
- SN United States
- BIIB United States
- Employees
- SN N/A
- BIIB N/A
- Industry
- SN
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- SN
- BIIB Health Care
- Exchange
- SN Nasdaq
- BIIB Nasdaq
- Market Cap
- SN 15.9B
- BIIB 18.7B
- IPO Year
- SN N/A
- BIIB 1991
- Fundamental
- Price
- SN $91.81
- BIIB $157.08
- Analyst Decision
- SN Strong Buy
- BIIB Buy
- Analyst Count
- SN 7
- BIIB 24
- Target Price
- SN $126.71
- BIIB $174.62
- AVG Volume (30 Days)
- SN 2.4M
- BIIB 1.6M
- Earning Date
- SN 11-06-2025
- BIIB 10-30-2025
- Dividend Yield
- SN N/A
- BIIB N/A
- EPS Growth
- SN 58.74
- BIIB N/A
- EPS
- SN 4.05
- BIIB 10.97
- Revenue
- SN $6,084,941,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- SN $18.26
- BIIB $2.97
- Revenue Next Year
- SN $11.75
- BIIB N/A
- P/E Ratio
- SN $22.69
- BIIB $14.28
- Revenue Growth
- SN 18.87
- BIIB 4.77
- 52 Week Low
- SN $60.50
- BIIB $110.04
- 52 Week High
- SN $128.51
- BIIB $179.20
- Technical
- Relative Strength Index (RSI)
- SN 45.73
- BIIB 64.92
- Support Level
- SN $83.12
- BIIB $148.90
- Resistance Level
- SN $98.47
- BIIB $155.33
- Average True Range (ATR)
- SN 4.28
- BIIB 4.79
- MACD
- SN 0.10
- BIIB 0.47
- Stochastic Oscillator
- SN 47.05
- BIIB 96.41
About SN SharkNinja Inc.
SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.